Acurx Pharmaceuticals Inc.
Organization details
- Legal name
- Acurx Pharmaceuticals Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Staten Island
- Headquarters state / province
- New York
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ACXP
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001736243
Board of directors
-
Carl Sailer · DirectorSince 2023
-
David P. Luci · Director · President and CEOSince 2023
-
Jack H. Dean · DirectorSince 2023
-
James J. Donohue · DirectorSince 2023
-
Joseph C. Scodari · DirectorSince 2023
-
Robert J. Deluccia · DirectorSince 2023
-
Thomas L. Harrison · DirectorSince 2023
Chief executives
Director election results
Annual meeting of October 16, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
94.2%
-
95.4%
Board connections
1 of this board's directors also sit on 2 other boards. 1 is in the same sector.
- via Thomas L. Harrison
-
Agenus Inc. Same sectorvia Thomas L. Harrison
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 6, 2025 | Joseph C. Scodari Director | Open-market purchase | +24,631 | $1.02 | $25,124 |
| Jan 6, 2025 | Carl Sailer Director | Open-market purchase | +24,631 | $1.02 | $25,124 |
| Jan 6, 2025 | David P. Luci Director, Officer (President and CEO), 10% owner | Open-market purchase | +49,261 | $1.02 | $50,246 |
| Jan 6, 2025 | James J. Donohue Director | Open-market purchase | +9,852 | $1.02 | $10,049 |
| Jan 6, 2025 | Robert J. Deluccia Director, 10% owner | Open-market purchase | +49,261 | $1.02 | $50,246 |
| Jan 6, 2025 | Jack H. Dean Director | Open-market purchase | +9,852 | $1.02 | $10,049 |
| Jan 19, 2024 | Carl Sailer Director | Option exercise | +19,737 | $3.55 | $70,066 |
| Jan 3, 2024 | David P. Luci Director, Officer (President and CEO), 10% owner | Option exercise | +19,737 | $3.55 | $70,066 |
| Jan 3, 2024 | Robert J. Deluccia Director, 10% owner | Option exercise | +19,737 | $3.55 | $70,066 |
| Dec 22, 2023 | Robert J. Deluccia Director, 10% owner | Gift | −30,000 | — | — |
| Dec 12, 2023 | Robert J. Deluccia Director, 10% owner | Gift | −40,000 | — | — |
| Dec 2, 2021 | Robert J. Deluccia Director, 10% owner | Gift | −40,000 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Acurx Pharmaceuticals Inc.
Who is the CEO of Acurx Pharmaceuticals Inc.?
David P. Luci is Acurx Pharmaceuticals Inc.'s President and CEO.
How many directors are on Acurx Pharmaceuticals Inc.'s board?
Acurx Pharmaceuticals Inc.'s board has 7 directors: Carl Sailer, David P. Luci, Jack H. Dean, James J. Donohue, Joseph C. Scodari, Robert J. Deluccia and Thomas L. Harrison.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="acurx-pharmaceuticals-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.